Sarepta Therapeutics is trading around $19 in extended hours following the FDA’s decision to remove the pause on Elevidys, marking a critical turning point for the beleaguered biotech. This regulatory ...
FILE PHOTO: A sign marks the offices of Sarepta Therapeutics in Cambridge, Massachusetts, U.S., . REUTERS/Brian Snyder/File Photo (Reuters) -Sarepta Therapeutics' shares plunged nearly 40 ...
MedCity News: Sarepta’s Future in Gene Therapy Remains Clouded, But Data From Partner Hansa Is a Bright Spot
Sarepta Therapeutics is still assessing how best to prevent liver injury from its commercialized Duchenne muscular dystrophy gene therapy. But Sarepta partner Hansa Biopharma has encouraging ...
Sarepta’s Future in Gene Therapy Remains Clouded, But Data From Partner Hansa Is a Bright Spot
Benzinga.com: What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
FiercePharma: Sarepta, with $1B in debts due in 2027, weighs efficiency measures
With more than $1 billion in debt due in 2027, Sarepta Therapeutics said it’s “evaluating opportunities to enhance operational efficiency and adjust manufacturing commitments based on latest demand.” ...
Sarepta Therapeutics (NASDAQ:SRPT) will release its quarterly earnings report on Monday, 2025-11-03. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Sarepta ...
MSN: Sarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial Results
We recently published 10 Stocks With Double-Digit Upsides. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top performers on Thursday. Sarepta Therapeutics extended its winning streak to a 5th ...